TAVR in Low-Risk Patients: FDA Approval, the New NCD, and Shared Decision-Making

Aortic stenosis (AS) is the most common valvular heart disease requiring intervention in the United States, and over the past decade, there has been a profound and rapid evolution in treatment paradigms. Based on an unprecedented clinical trial effort, transcatheter aortic valve replacement (TAVR)